Clinical Laserthermia Systems AB (publ) publishes Annual report 2022
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) announces today that the Company’s Annual report for 2022 has been published.
The annual report in Swedish is available on the company’s website www.cinicallaser.se. An English version of the annual report will be published on the company’s website in June.
”CLS achieved several important milestones during 2022 and the company has primarily focused on creating good conditions for accelerated growth and commercialization through new partnerships, advancements in our clinical studies and progress within in the regulatory area. The company has also strengthened its branding and communication efforts, primarily in the American market, as part of paving the way for coming sales activity.
We now face a very exciting future and I look forward to continuing to contribute to improved treatments and increased quality of life for cancer patients and patients with neurological diseases, together with employees and shareholders,” says Dan Mogren, CEO CLS.
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: [email protected]
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: [email protected].
For more information about CLS, please visit the Company's website: clinicallaser.se
This disclosure contains information that CLS is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 29-05-2023 20:00 CET.